Categories: Wire Stories

InnoCare Announces First Subject Dosed in Clinical Trial of Novel Targeted Protein Degrader ICP-490 in China

BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first subject has been dosed in clinical trial of the Company�s novel targeted protein degrader ICP-490 in China.

ICP-490 is developed from InnoCare’s molecular glue platform for the treatment of multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL). It can overcome acquired resistance against earlier-generation of CRBN modulators. Synergizing and enhancing efficacy of monoclonal antibodies (mAbs), ICP-490 provides strong rationale of synergistic combinations in the clinic, and demonstrates immense potential in hematology field.

ICP-490 is expected to demonstrate anti-tumor effects in various MM and diffuse large B cell lymphoma (DLBCL). In addition, by enhancing its ADCC activity, ICP-490 can synergize with InnoCare’s drug pipelines, such as tafasitamab, which provides scientific rationales for combinatory treatment in the clinic.

Dr. Jasmine Cui, the Co-founder, Chairwoman and CEO of InnoCare said, “ICP-490 is a highly potent next generation CRBN Modulator. Developed for the treatment of multi-indications, it has the potential to become a blockbuster in our blood tumor pipeline. We will accelerate its clinical development and explore single or combined therapies, expecting to benefit the blood tumor patients early.”

MM accounts for about 10 percent of blood tumors1. NHL is the most common hematological malignancy in the world2, ranking among the top 10 common malignant tumors in China.

About InnoCare

InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases with unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and United States.

InnoCare Forward-looking Statements

This report contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management’s intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance.

1 Yongchao Liang et al., 2021

2 Thakurta et al., 2021

Contacts

Media
Chunhua Lu

86-10-66609879

chunhua.lu@innocarepharma.com

Investors
86-10-66609999

ir@innocarepharma.com

Alex

Recent Posts

Carta continues with global expansion in Australia to support the country’s local startup and investor ecosystem

The US-based private capital software platform sets up base in Sydney as part of Investment…

14 mins ago

Mastering exotic currency pairs: trading strategies with global broker Octa

KUALA LUMPUR, MALAYSIA - Media OutReach Newswire - 14 November 2024 - Adding exotic currency…

59 mins ago

SIBUR to Offset Carbon Footprint of Russia’s COP29 Delegation

MOSCOW, RUSSIA - Media OutReach Newswire - 14 November 2024 - SIBUR plans to offset…

59 mins ago

St. George’s University Invites South Korean Students to Apply for January 2025 Intake

SEOUL, SOUTH KOREA - Media OutReach Newswire - 14 November 2024 - St. George’s University…

3 hours ago

Swiss Business Hub: Global Fintechs Thrive on Switzerland’s Tech-Neutral Approach to AI

SINGAPORE - Media OutReach Newswire - 14 November 2024 - In the rapidly evolving landscape…

11 hours ago

CGTN:G20 pushes for global cooperation to eradicate hunger and poverty

BEIJING, CHINA - Media OutReach Newswire - 13 November 2024 - The first-ever Global Alliance…

11 hours ago